MAP2K7 and acute lymphoblastic leukemia: To test the effect of MAP2K7 inhibition in T-ALL patient samples, we generated a panel of four T-ALL patient-derived xenograft (PDX) cells and evaluated sensitivity to 5Z7O treatment.